According to Zhitong Finance App News, McPharmaceutical-B (02335.HK) issued an announcement. In the critical phase III clinical trial of the company's core product MT1013, all participants have completed the follow-up procedures stipulated in the study, treatment, and all trial plans, and have already left the team.

Zhitongcaijing · 11/09 04:17
According to Zhitong Finance App News, McPharmaceutical-B (02335.HK) issued an announcement. In the critical phase III clinical trial of the company's core product MT1013, all participants have completed the follow-up procedures stipulated in the study, treatment, and all trial plans, and have already left the team.